Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03645876
Other study ID # SHR-1210-II-210
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 8, 2018
Est. completion date April 18, 2019

Study information

Verified date May 2019
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.

SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a humanized recombinant monoclonal IgG1 antibody.

The primary objective of this study is to investigate the safety and efficacy of the subjects who given the combination therapy.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date April 18, 2019
Est. primary completion date April 18, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Age =18 and =75 years old;

2. Histologically confirmed colorectal cancer with a metastatic / recurrent lesion that cannot be cured by surgery.

3. At least one measurable lesion have been the confirmatory detection respect to RECIST 1.1

4. No prior first-line systemic anti-tumor therapy for mCRC (including systemic chemotherapy, molecular targeted therapy, biotherapy, immunotherapy, radiotherapy, local therapy and other study treatment) have been identified

5. At least 6 months have elapsed if considering the interval from the time of firstly documented metastasis to the post-operational adjuvant chemotherapy termination

6. Can provide either a newly obtained or archival tumor tissue sample.

7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

8. Life expectancy = 3 months

9. Subjects must have normal organ and marrow function as defined below:

1. Absolute neutrophil count (ANC) =1,500 /mm3(1.5×109 /L)

2. Platelets =90,000 / mm3(90×109 /L)

3. Hemoglobin =10 g/dL, within the 2 weeks prior to the screening no need for the transfusion

4. Serum albumin =2.8 g/dL

5. Total bilirubin= 1.5 X ULN, AST (SGOT), ALT (SGPT) = 2.5 X ULN (AST/ALT = 5 X ULN if liver metastatic);

6. Creatinine clearance = 50 mL/min according to Cockcroft-Gault formula

10. For females of child bearing potential, a negative urine or serum pregnancy test result within 72h before study treatment. Participants of reproductive potential must be willing to use adequate contraception for the course of the study until 3 months after the last dose of any of the drugs in the study.

11. The subjects are accredited with good compliance, signed the informed consent, and capable to cooperate, completing the relevant examination and follow-ups.

Exclusion Criteria:

1. Prior first-line systemic anti-tumor therapy for mCRC (including systemic chemotherapy, molecular targeted therapy, immunotherapy, biotherapy, and other treatment).

2. The metastatic/recurrent lesion is subject to be cured by surgical intervention.

3. Major operation or open biopsy or major trauma within 4 weeks prior to first dose.

4. Known Cerebral and/or leptomeningeal metastasis.

5. Bleeding predisposition, high bleeding risk or coagulant disorder, thrombotic event(s) occurrence =6 months and/or hemoptysis =3 months (= 1/2 teaspoons fresh blood each) prior to the screening; use of full dose oral or parenteral anticoagulant or thrombolytic medication (allowing preventative anticoagulation); use of aspirin (> 325 mg/day) or other platelet-inhibition non-steroidal anti-inflammatory drugs within 10 days since the screening; CT/MRI imaging evidence, testimony of the main arteries/veins (such as pulmonary artery or superior vena cava) being infringed, encroached

6. Subjects with uncontrolled hypertension and with a medical history of hypertensive crisis or hypertensive encephalopathy; serious cardiovascular and cerebrovascular diseases, including cerebrovascular accident (CVA) =6 months before the screening, transient ischemic attack (TIA), myocardial infarction and significant vascular disease (including but not limited to aortic aneurysms with need for surgical repair or recent evidence of arterial thrombosis), unstable angina, heart failure and serious arrhythmias that are uncontrolled by drugs (New York Heart Association Class =2).

7. Subjects with non-healing wounds, active peptic ulcer or fracture and active infection; tracheal esophageal fistula, gastrointestinal perforation or gastrointestinal fistula and abdominal abscess in the 6 months prior to the screening.

8. Subjects with any active autoimmune disease or history of autoimmune disease

9. Active infection or an unexplained fever > 38.5°C before two weeks of randomization (subjects with tumor fever may be enrolled at the discretion of the investigator);

10. History of Interstitial Pneumonia or received Corticosteroids for non-infectious pneumonitis.

11. Known Human Immunodeficiency Virus (HIV) infection?active Hepatitis B or Hepatitis C.

12. Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR-1210 or BP102 formulation, allergy, hypersensitivity, or contraindication to oxaliplatin, or Capecitabine

13. Currently participating or has participated in a study within 4 weeks of the first dose of study medication.

14. Has a known additional malignancy within the last 5 years before study treatment with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers

15. Received a live vaccine within 4 weeks of the first dose of study medication

16. Pregnancy or breast feeding.

17. According to the investigator, other conditions that may lead to stop the research.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SHR-1210
200mg
BP102
7.5mg/kg
oxaliplatin
130mg/m2
capecitabine
1000mg/m2

Locations

Country Name City State
China Cancer Center of Sun-Yat Sen University (CCSYSU) Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Biomarkers and ADA PD-L1?MSI?TMB expression and ADA 24 months
Primary Safety of the combination therapy: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment From sign icf to the end of follow-up 24 months
Primary Objective response rate From sign icf to occurrence of objective response (complete regression (CR) and partial regression (PR) need to be confirmed 28 days after the occurrence) 24 months
Secondary DOR Duration of response ,DOR 24 months
Secondary DCR Disease Control Rate,DCR 24 months
Secondary PFS Progression free survival,PFS 24 months
Secondary 9month PFS rate Month 9 PFS rate,PFS9m 9 months
Secondary 12month and 24 month OS rate Overall survival rate: the time from the date of icf to the date of documented clinical or radiological progression or death due to any cause within 12 and 24 months after first visit 24 months
See also
  Status Clinical Trial Phase
Completed NCT01228734 - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. Phase 1/Phase 2
Withdrawn NCT05412706 - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy Phase 2
Withdrawn NCT04430985 - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer Phase 2
Withdrawn NCT03182894 - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05725200 - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer Phase 1
Completed NCT04866290 - HepaSphere™ Microspheres Prospective Registry
Not yet recruiting NCT06425133 - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers Phase 2
Not yet recruiting NCT05531045 - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02906059 - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02575378 - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Phase 4
Withdrawn NCT02535988 - Abscopal Effect for Metastatic Colorectal Cancer Phase 2
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT02077868 - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3
Completed NCT02414009 - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Phase 2
Active, not recruiting NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Phase 2
Withdrawn NCT01915472 - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2